BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20251108T171231EST-5037WNfsjs@132.216.98.100
DTSTAMP:20251108T221231Z
DESCRIPTION:Abstract:\n\nSuccessful tumors are able to evade the immune sys
 tem\, which is otherwise capable of killing transformed cells. Therapies t
 hat prevent this evasion have become revolutionary treatments for incurabl
 e cancers. This presentation will focus on our recent work targeting immun
 e suppressive Siglec receptors and their sialylated glycan ligands\, which
  are abundant within the cancer glycocalyx. We found that Siglec-ligand in
 teractions can confer resistance to antibody-dependent cell cytotoxicity\n
 	mediated by monoclonal antibody cancer drugs such as Herceptin. Based on t
 his\, we designed biotherapeutic molecules termed antibody-enzyme conjugat
 es that selectively remove sialic acids from tumor cells and render them s
 usceptible to immune cell killing. Editing the cancer cell glycocalyx with
  antibody-enzyme conjugates represents a new approach to cancer immune the
 rapy.\n\nBio:\n\nCarolyn Bertozzi is the Anne T. and Robert M. Bass Profes
 sor of Chemistry and Professor of Chemical & Systems Biology and Radiology
  (by courtesy) at Stanford University\, and an Investigator of the Howard 
 Hughes Medical Institute. She completed her undergraduate degree in Chemis
 try from Harvard University in 1988 and her Ph.D. in Chemistry from UC Ber
 keley in 1993. After completing postdoctoral work at UCSF in the field of 
 cellular immunology\, she joined the UC Berkeley faculty in 1996. In June 
 2015\, she joined the faculty at Stanford University coincident with the l
 aunch of Stanford's ChEM-H institute.\n\nProf. Bertozzi's research interes
 ts span the disciplines of chemistry and biology with an emphasis on studi
 es of cell surface glycosylation pertinent to disease states. Her lab focu
 ses on profiling changes in cell surface glycosylation associated with can
 cer\, inflammation and bacterial infection\, and exploiting this informati
 on for development of diagnostic and therapeutic approaches\, most recentl
 y in the area of immuno-oncology. She has been recognized with many honors
  and awards for her research accomplishments. She is an elected member of 
 the Institute of Medicine\, National Academy of Sciences\, and American Ac
 ademy of Arts and Sciences. She has been awarded the Lemelson-MIT Prize\, 
 the Heinrich Wieland Prize\, and a MacArthur Foundation Fellowship\, among
  many others.\n
DTSTART:20181211T180000Z
DTEND:20181211T193000Z
LOCATION:Room 10\, Maass Chemistry Building\, CA\, QC\, Montreal\, H3A 0B8\
 , 801 rue Sherbrooke Ouest
SUMMARY:The 2018/2019 J.T. Donald Lecture: Carolyn Bertozzi - Targeting the
  Glycocalyx for Cancer Immune Therapy
URL:/chemistry/channels/event/20182019-jt-donald-lectu
 re-carolyn-bertozzi-targeting-glycocalyx-cancer-immune-therapy-290128
END:VEVENT
END:VCALENDAR